Prostaglandins for induction in pregnancies with fetal growth restriction.
Publication/Presentation Date
3-1-2022
Abstract
BACKGROUND: The data on safety of prostaglandin agents for induction of pregnancies with fetal growth restriction is limited.
OBJECTIVE: To compare the rates of adverse outcomes among pregnancies with fetal growth restriction undergoing induction of labor with and without prostaglandins STUDY DESIGN: We performed a propensity-score-based secondary analysis of the Consortium on Safe Labor database. We included term, singleton, and nonanomalous pregnancies with fetal growth restriction (estimated fetal weight < 10th percentile for gestational age). We excluded previous cesarean deliveries. The primary exposure was induction using prostaglandins (prostaglandin E
RESULTS: Of 756 (0.3%) inductions, 212 (28%) used prostaglandins (108 prostaglandin E
CONCLUSION: There were no differences in the composite of adverse neonatal outcomes when prostaglandins were used for induction in pregnancies with fetal growth restriction compared with other methods. However, there was a higher rate of cesarean delivery and cesarean delivery indicated for nonreassuring fetal heart tracings when prostaglandins (both prostaglandin E
Volume
4
Issue
2
First Page
100538
Last Page
100538
ISSN
2589-9333
Published In/Presented At
Al-Hafez, L., Bicocca, M. J., Chauhan, S. P., & Berghella, V. (2022). Prostaglandins for induction in pregnancies with fetal growth restriction. American journal of obstetrics & gynecology MFM, 4(2), 100538. https://doi.org/10.1016/j.ajogmf.2021.100538
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
34813974
Department(s)
Administration and Leadership
Document Type
Article